Cargando…

Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy

The standard treatment for advanced thymic carcinoma has not yet been established. Most patients have no symptoms until the advanced stage. Radiation therapy has been used for advanced stage cancer, usually in combination with surgery or chemotherapy; however, the survival rates are 30%-50%. We perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Yuko, Miyazaki, Shinichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364086/
https://www.ncbi.nlm.nih.gov/pubmed/28367393
http://dx.doi.org/10.7759/cureus.1056
_version_ 1782517254519259136
author Harada, Yuko
Miyazaki, Shinichiro
author_facet Harada, Yuko
Miyazaki, Shinichiro
author_sort Harada, Yuko
collection PubMed
description The standard treatment for advanced thymic carcinoma has not yet been established. Most patients have no symptoms until the advanced stage. Radiation therapy has been used for advanced stage cancer, usually in combination with surgery or chemotherapy; however, the survival rates are 30%-50%. We performed hypofractionated stereotactic radiotherapy with CyberKnife (Accuray, Sunnyvale, CA, USA) for 10 cases of advanced thymic cancer. All cases reached at least partial remission (PR) in two months with progression-free irradiated lesions and minimal radiation-related toxicity. It took only seven to 12 days for each therapy that did not require admission. CyberKnife is beneficial for patients even at the terminal stage.
format Online
Article
Text
id pubmed-5364086
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-53640862017-03-31 Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy Harada, Yuko Miyazaki, Shinichiro Cureus Radiation Oncology The standard treatment for advanced thymic carcinoma has not yet been established. Most patients have no symptoms until the advanced stage. Radiation therapy has been used for advanced stage cancer, usually in combination with surgery or chemotherapy; however, the survival rates are 30%-50%. We performed hypofractionated stereotactic radiotherapy with CyberKnife (Accuray, Sunnyvale, CA, USA) for 10 cases of advanced thymic cancer. All cases reached at least partial remission (PR) in two months with progression-free irradiated lesions and minimal radiation-related toxicity. It took only seven to 12 days for each therapy that did not require admission. CyberKnife is beneficial for patients even at the terminal stage. Cureus 2017-02-26 /pmc/articles/PMC5364086/ /pubmed/28367393 http://dx.doi.org/10.7759/cureus.1056 Text en Copyright © 2017, Harada et al. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiation Oncology
Harada, Yuko
Miyazaki, Shinichiro
Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title_full Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title_fullStr Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title_full_unstemmed Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title_short Thymic Carcinoma Treated by CyberKnife Stereotactic Body Radiotherapy
title_sort thymic carcinoma treated by cyberknife stereotactic body radiotherapy
topic Radiation Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5364086/
https://www.ncbi.nlm.nih.gov/pubmed/28367393
http://dx.doi.org/10.7759/cureus.1056
work_keys_str_mv AT haradayuko thymiccarcinomatreatedbycyberknifestereotacticbodyradiotherapy
AT miyazakishinichiro thymiccarcinomatreatedbycyberknifestereotacticbodyradiotherapy